Symphogen enters into a collaboration with Aarhus University/Department of Infectious Disease to identify COVID-19 neutralizing antibodies for the potential prevention and treatment of COVID-19 https://health.au.dk/en/#news-17843
The CoroNAT project is supported by Innovation Fund Denmark https://innovationsfonden.dk/da/nyheder-presse-og-job/se-hvilke-covid-19-projekter-innovationsfonden-investerer-i
About Symphogen
Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use in oncology. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product. The company has collaborations for the development of antibody therapeutics in the infectious disease area with Genentech, and in immuno-oncology with Shire. Symphogen has offices in Denmark and New Jersey, US and its investors include Essex Woodlands Health Ventures, Novo A/S, PKA, Sunstone Capital, Gilde Healthcare Partners, Danica Pension, Takeda Ventures, Inc., and Genentech.